Abstract
This review will focus on the drug information of Venetoclax, a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality, in adults with 17p deletion. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) proteins, which supports cancer cell growth and is over expressed in many patients with CLL.
Venetoclax is used a second line treatment for chronic lymphocytic leukemia, only if there is a 17p deletion. Venclexta (venetoclax) inhibits a certain protein in cancer cells (abnormal lymphocytes produced in chronic lymphocytic leukemia) that helps keep those cells alive and makes them resistant to chemotherapy. Venetoclax binds to this protein, which helps kill the cancerous lymphocytes in blood and bone marrow. Venclexta is usually given after at least one other cancer medicine has been tried without success.
Keywords: Venetoclax, chronic lymphocytic leukemia.
References
1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 111" (PDF). WHO Drug Information. 2014:28 (2):270.
2. http://adisinsight.springer.com/drugs/800034622, Drug Profile, Venetoclax, Accessed 11 March 2017.
3. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality, Accessed 11 Mar 2017
4. The medical letter on drug and therapeutics , August 1, 2016, Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
5. http://www.ema.europa.eu/ema"CHMP summary of positive opinion for Venclyxto". European Medicines Agency. Accessed 11 March 2017.
6. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm"Press Announcements - FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality".Accessed 11 March 2017.
7. http://www.biopharmadive.com/news/ "Inside the development of Venclexta, AbbVie's new leukemia drug". BioPharma Dive.Accessed 11 March 2017.
8. http://images.info.science.thomsonreuters.biz/Web/ThomsonReutersScience,"Drugs to Watch 2016 - Market Insight Report" (PDF), Accessed 11 March 2017
9. http://www.onclive.com/web-exclusives "Ibrutinib and Idelalisib Cont-inue to Impress in CLL, May Eventually Replace Chemotherapy for Some Pati-ents". OncLive. .Accessed 11 March 2017
10. "United States Patent: 9174982".http : patft.uspto.gov.Accessed 11 March 2017.
11. "Drugs to Watch 2016 - Market Insight Report" (PDF). Thomson Reuters. Accessed 11 March 2017
12. https://www.venclexta.com, Medicationguide , Venclexta Accessed 11March 2017 .
13. http://www.wehi.edu.au/research-research-fields/clinical-translation/venetoclax Accessed 11 March 2017
Corresponding Author
Ragav S R
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mobile No: +91 9941691694
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.45
